^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cobolimab (TSR-022)

    i
    Other names: TSR-022, TSR 022, WBP 296A, GSK4069889, WBP-296A, WBP296A, GSK-4069889, GSK 4069889, TSR022
    Company:
    AnaptysBio, GSK
    Drug class:
    TIM-3 antagonist
    Related drugs:
    23d
    A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer (clinicaltrials.gov)
    P1/2, N=83, Active, not recruiting, GlaxoSmithKline | Trial completion date: Jan 2032 --> Oct 2026 | Trial primary completion date: Jan 2032 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)
    1m
    A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (clinicaltrials.gov)
    P1, N=463, Active, not recruiting, Tesaro, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2025 --> Mar 2027
    Enrollment closed • Trial primary completion date
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • docetaxel • pemetrexed • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • encelimab (TSR-033)
    1m
    Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=107, Active, not recruiting, GlaxoSmithKline | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • belrestotug (EOS-448) • nelistotug (GSK6097608)
    2ms
    Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 (clinicaltrials.gov)
    P1, N=60, Completed, Tesaro, Inc. | Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Dec 2024
    Trial completion • Trial completion date
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • Zejula (niraparib) • albumin-bound paclitaxel • pemetrexed • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)
    2ms
    COSTAR Lung: Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy (clinicaltrials.gov)
    P3, N=758, Active, not recruiting, GlaxoSmithKline | Trial completion date: Oct 2025 --> Mar 2027
    Trial completion date
    |
    docetaxel • Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)
    4ms
    A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer (clinicaltrials.gov)
    P1/2, N=95, Active, not recruiting, GlaxoSmithKline | Trial primary completion date: Oct 2029 --> Jan 2032 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial primary completion date
    |
    Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)
    5ms
    Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B. (PubMed, Clin Cancer Res)
    Cobolimab plus dostarlimab showed preliminary efficacy and tolerability in a subset of patients with locally advanced/metastatic NSCLC. See related article by Davar et al., p. XX.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)
    5ms
    Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A. (PubMed, Clin Cancer Res)
    In this exploratory setting, cobolimab plus dostarlimab was well tolerated, with reported preliminary efficacy similar to other anti-T-cell immunoglobulin and mucin-domain containing protein-3 treatments in patients with locally advanced/metastatic melanoma. See related article by Davar et al., p. XX.
    Journal
    |
    PD-1 (Programmed cell death 1) • HAVCR2 (Hepatitis A Virus Cellular Receptor 2)
    |
    Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)
    9ms
    Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=107, Active, not recruiting, GlaxoSmithKline | Recruiting --> Active, not recruiting | N=244 --> 107 | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2025 --> Dec 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    Jemperli (dostarlimab-gxly) • cobolimab (TSR-022) • belrestotug (EOS-448) • nelistotug (GSK6097608)
    9ms
    A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer (clinicaltrials.gov)
    P1/2, N=95, Recruiting, GlaxoSmithKline | Trial completion date: Nov 2030 --> Jan 2032 | Trial primary completion date: Aug 2028 --> Oct 2029
    Trial completion date • Trial primary completion date
    |
    Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)
    12ms
    A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer (clinicaltrials.gov)
    P1/2, N=95, Recruiting, GlaxoSmithKline | Not yet recruiting --> Recruiting | Initiation date: Sep 2024 --> Dec 2024
    Enrollment open • Trial initiation date
    |
    Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)
    1year
    TSR-022 (anti-TIM-3 Antibody) and TSR-042 (anti-PD-1 Antibody) in Patients with Liver Cancer (clinicaltrials.gov)
    P2, N=42, Active, not recruiting, University of Hawaii | Trial primary completion date: Oct 2024 --> Oct 2025
    Trial primary completion date • Combination therapy • Metastases
    |
    Jemperli (dostarlimab-gxly) • cobolimab (TSR-022)